Evidence map›Paper›PMID 37333254›Full record

ArticlebioRxiv : the preprint server for biology2023

Extracellular cysteine disulfide bond break at Cys122 disrupts PIP

Francisco M Cruz, Álvaro Macías, Ana I Moreno-Manuel, Lilian K Gutiérrez, María Linarejos Vera-Pedrosa, Isabel Martínez-Carrascoso, Patricia Sánchez Pérez, Juan Manuel Ruiz Robles, Francisco J Bermúdez-Jiménez, Aitor Díaz-Agustín and 9 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Francisco M CruzCentro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Álvaro MacíasCentro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Ana I Moreno-ManuelCentro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Lilian K GutiérrezCentro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
María Linarejos Vera-PedrosaCentro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Isabel Martínez-CarrascosoCentro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Patricia Sánchez PérezCentro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Juan Manuel Ruiz RoblesCentro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Francisco J Bermúdez-JiménezCentro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Aitor Díaz-AgustínInstituto de Química Médica (IQM), Consejo Superior de Investigaciones Científicas (CSIC), 28006 Madrid, Spain.
Fernando Martínez de BenitoCentro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Salvador Arias SantiagoServicio de Dermatología Hospital Universitario Virgen de las Nieves.
Aitana Braza-BoilsUnit of Inherited Cardiomyopathies and Sudden Death (CAFAMUSME), Health Research Institute La Fe, La Fe Hospital, Valencia, Spain.
Mercedes Martín-MartínezInstituto de Química Médica (IQM), Consejo Superior de Investigaciones Científicas (CSIC), 28006 Madrid, Spain.
Marta Gutierrez-RodríguezInstituto de Química Médica (IQM), Consejo Superior de Investigaciones Científicas (CSIC), 28006 Madrid, Spain.
Juan A BernalCentro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Esther ZorioCIBER de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Juan Jiménez-JaimezServicio de Cardiología, Hospital Universitario Virgen de las Nieves, Granada, Spain.
José JalifeCentro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain.
Spanish National Centre for Cardiovascular Research · ESConsejo Superior de Investigaciones Científicas · ESHospital Universitari i Politècnic La Fe · ESInstituto de Investigación Biosanitaria de Granada · ESUniversity of Michigan · US

Funding

Peptibodies As Novel Therapies in Atrial FibrillationR01HL163943 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI Sami Fouad Noujaim, MICHAEL N TENG · 2023 to 2026
$2.4M
NHLBI NIH HHS R01 HL163943
6 · The paper itself

Abstract

Background: Andersen-Tawil Syndrome Type 1 (ATS1) is a rare heritable disease caused by mutations in the strong inwardly rectifying K Methods and Results: We identified a Kir2.1 loss-of-function mutation in Cys122 (c.366 A>T; p.Cys122Tyr) in a family with ATS1. To study the consequences of this mutation on Kir2.1 function we generated a cardiac specific mouse model expressing the Kir2.1 Conclusion: The extracellular Cys122-to-Cys154 disulfide bond in the tridimensional Kir2.1 channel structure is essential to channel function. We demonstrated that ATS1 mutations that break disulfide bonds in the extracellular domain disrupt PIP

Indexed as

ArrhythmiasIon channel diseasesKir2.1-PIP2 interactionMolecular DynamicsSudden Cardiac Death

Identifiers

PMID37333254
PMCPMC10274791
OpenAlexW4379985773

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.